NEW YORK - Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), a biopharmaceutical company specializing in cancer treatment therapies, recently announced the appointment of Peter Pfreundschuh as its new Chief Financial Officer. Mr. Pfreundschuh, whose tenure began on Monday, will be reporting directly to President and CEO Mike Rossi.
The company is at a pivotal juncture with its U.S. commercialization of DANYELZA® and the advancement of its innovative Self-Assembly DisAssembly Pretargeted Radioimmunotherapy (SADA-PRIT) technology platform.
Rossi expressed confidence that Pfreundschuh's extensive experience in healthcare leadership and his track record in commercializing pharmaceutical products will significantly contribute to Y-mAbs' strategic decision-making and ongoing mission to improve patient lives.
Pfreundschuh's career spans various executive roles in notable healthcare companies, including his most recent position as CFO at Voyager Therapeutics (NASDAQ:VYGR), Inc. His previous engagements include leadership positions at Frequency Therapeutics, Inc., UroGen Pharma Ltd., and other companies within the sector.
He also brings a wealth of experience from his time at Johnson & Johnson (NYSE:JNJ) and AstraZeneca (NASDAQ:AZN), commencing his career at Ernst & Young, LLP.
Excited to join the team, Pfreundschuh highlighted the company's strong financial foundation and the global commercial success of DANYELZA®. He looks forward to furthering the development of the SADA-PRIT technology platform, which has the potential to transform the use of radiopharmaceutical therapies.
Y-mAbs Therapeutics focuses on developing and commercializing novel treatments for cancer, including radioimmunotherapy and antibody-based therapies. Their pipeline features DANYELZA®, an FDA-approved therapy for high-risk neuroblastoma patients.
The information in this article is based on a press release statement by Y-mAbs Therapeutics, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.